Artal Group S.A. Vaxart, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$3.5 - $7.98 $2.63 Million - $5.99 Million	-750,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.78 - $16.97 $2.63 Million - $9.33 Million	550,000 Added 275.0%	750,000 $4.99 Million
Q2 2020 Aug 14, 2020	BUY	$1.68 - $8.85 $336,000 - $1.77 Million	200,000 New	200,000 $1.77 Million

109

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $68.3M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.